0001104659-21-013180.txt : 20210205
0001104659-21-013180.hdr.sgml : 20210205
20210205201641
ACCESSION NUMBER: 0001104659-21-013180
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210204
FILED AS OF DATE: 20210205
DATE AS OF CHANGE: 20210205
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Oliviero James F III
CENTRAL INDEX KEY: 0001434718
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38128
FILM NUMBER: 21598224
MAIL ADDRESS:
STREET 1: C/O KERYX BIOPHARMACEUTICALS, INC.
STREET 2: 750 LEXINGTON AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10022
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Checkpoint Therapeutics, Inc.
CENTRAL INDEX KEY: 0001651407
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 472568632
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2 GANSEVOORT STREET
STREET 2: 9TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10014
BUSINESS PHONE: 212-554-4366
MAIL ADDRESS:
STREET 1: 2 GANSEVOORT STREET
STREET 2: 9TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10014
4
1
tm215541-2_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2021-02-04
0
0001651407
Checkpoint Therapeutics, Inc.
CKPT
0001434718
Oliviero James F III
2 GANSEVOORT ST, 9TH FLOOR
NEW YORK
NY
10014
1
1
0
0
CEO, President and Director
COMMON STOCK
2021-02-04
4
S
0
70000
3.5075
D
3202000
D
COMMON STOCK
2021-02-05
4
S
0
48790
3.4176
D
3153210
D
In connection with the vesting of 243,750 shares, these shares were sold by the Company's restricted stock administrator in order to satisfy Mr. Oliviero's tax withholding obligations. Mr. Oliviero had no discretion with respect to such sale, which was transacted by the Company in accordance with the Company's corporate policies regarding the vesting of restricted stock.
Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $3.50 to $3.525. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.
Represents the weighted average price of the shares sold in this transaction. The range of prices for such transaction was $3.35 to $3.52. The reporting person undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price.
Includes shares of restricted Common Stock, which vest over various time periods
/s/ James F. Oliviero, III
2021-02-05